KDR and ovarian cancer: Levels of CD34 were not significantly different in pre-treatment ovarian cancer patients compared with healthy controls (Fig. 2A), whereas VEGFR2 expression in pre-treatment ovarian cancer patients was 61-fold higher compared with healthy controls (P = 0.013) (Fig. 2B).